drugset
drugset / Trial / NCT05789602

A Study of BPI-460372 in Advanced Solid Tumor Patients

NCT05789602 ↗

Phase 1 Recruiting 82 enrolled Betta Pharmaceuticals Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.

Timeline

Start
2023-04-24
Primary completion
2025-04-17
Completion
2026-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BPI-460372 Unknown — Oral

Indications

neoplasm